Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

QR-504a

Other · developed by ProQR Therapeutics

Phase 1 Most advanced trial (none active)

PRQR Developer

1 Registered trials

What is QR-504a?

QR-504a is an investigational drug studied in Fuchs Endothelial Corneal Dystrophy, FECD3, Corneal Diseases.

At a glance

Drug type: Other
Therapy area: Ophthalmology
Developer: ProQR Therapeutics (PRQR)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT05052554	Phase 1	Fuchs Endothelial Corneal Dystrophy	Withdrawn	PRQR

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Corneal DiseasesDescemet's Membrane DisorderFECD3Fuchs Endothelial Corneal DystrophyLRS

More from ProQR Therapeutics

QR-010 Phase 1/2 QR-1123 Phase 1/2 QR-421a Phase 1/2 Sepofarsen Phase 2/3

Sources

ClinicalTrials.gov NCT05052554

Updated Oct 3, 2026. Something wrong or missing? Report it on the PRQR page.

Follow PRQR, the company behind QR-504a

See PRQR's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

PRQR catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z